Mode
Text Size
Log in / Sign up
Phase 4 N=49 Randomized Single-blind Treatment

Intramuscular Epinephrine as an Adjunctive Treatment for Severe Pediatric Asthma Exacerbation

Asthma

Enrolled (actual)
49
Serious AEs
0.0%
Results posted
Jul 2021
Primary outcome: Primary: Change in Percent of Predicted Peak Expiratory Flow Rate (PEFR) at t15 — 59.56; 52.45 percentage of predicted

Study Design & Population

Study type
Interventional
Phase
Phase 4
Interventions
IM epinephrine 1:1000 (Drug); No intervention (Other)
Age
Pediatric · 6+ yrs
Sex
All
Sponsor
University of Louisville
Primary completion
Apr 2018

Outcome Measures

OutcomeResultp-value
PRIMARY
Change in Percent of Predicted Peak Expiratory Flow Rate (PEFR) at t15
59.56; 52.45
SECONDARY
Disposition
15; 12
SECONDARY
Change in Percent of Predicted PEFR at t120
64.51; 56.18
SECONDARY
Breaths Per Minute at t120
24.29; 29.29
SECONDARY
Heart Rate at t120
147.65; 142.29

Summary

Project Aim: To determine if intramuscular epinephrine is an effective adjunct to inhaled bronchodilators (β2 agonists) for children with severe asthma exacerbation. Hypothesis: IM epinephrine is an efficacious adjunct to inhaled bronchodilators (β2 agonists) for children with severe asthma exacerbation. Intervention: Subjects will be randomly assigned (50% chance) to receive a weight based dose of IM epinephrine 1:1000 or no adjunctive medication. The dose will be 0.2 mg for subjects 20-30 kg and 0.3 mg for subjects greater than 30 kg. This will be injected intramuscularly by an ED nurse into the anterior thigh muscles of the subject using a 1 ml syringe and a 23 gauge one inch needle. In addition to the study intervention, the standardized treatment pathway based on the current asthma guidelines in use at the investigator's center will be utilized. This pathway includes nebulized albuterol, ipratropium bromide, and systemic corticosteroids. The duration and dosages of these other interventions will be administered at the discretion of the treating provider.

Eligibility Criteria

Inclusion Criteria

  • Age greater than 6 years and less than 18 years
  • Pre-existing diagnosis of asthma
  • Presenting to the ED with an asthma exacerbation

Exclusion Criteria

  • History of chronic lung or upper airway disease other than asthma
  • History significant, uncorrected congenital heart disease or cardiac arrhythmia
  • History of thyroid disease
  • Impending respiratory failure
  • Allergy to epinephrine
  • Pregnancy
  • PEFR>60% of predicted and clinical asthma score less than 8
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01705964). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search